| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe |
| Completed | 1b | 20 | Europe | VX-950, peginterferon | Vertex Pharmaceuticals Incorporated | Hepatitis C | | 03/06 | | |
NCT00509210: Study of Telaprevir in Subjects With Hepatic Impairment |
|
|
| Completed | 1 | | US | telaprevir (VX-950) | Vertex Pharmaceuticals Incorporated | Hepatic Insufficiency | 06/08 | 06/08 | | |
NCT00591214: Safety and PK Study of MP-424 to Treat Chronic Hepatitis C |
|
|
| Completed | 1 | 10 | Japan | MP-424 (Telaprevir) | Mitsubishi Tanabe Pharma Corporation, Vertex Pharmaceuticals Incorporated | Chronic Hepatitis C | 10/08 | 10/08 | | |
NCT00775125: VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state. |
|
|
| Completed | 1 | 40 | RoW | Telaprevir; Darunavir; Ritonavir; Fosamprenavir | Tibotec BVBA | Hepatitis C, Telaprevir, HIV | 10/08 | 10/08 | | |
NCT00630058: A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C |
|
|
| Completed | 1 | 20 | Japan | MP-424(H), PEG-IFN-a-2b, RBV, Telaprevir, MP-424 (L), PEG-IFN-a-2b, RBV | Mitsubishi Tanabe Pharma Corporation, Vertex Pharmaceuticals Incorporated | Hepatitis C | 03/09 | 03/09 | | |
NCT00828789: VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer |
|
|
| Completed | 1 | 20 | RoW | Efavirenz; Tenofovir disoproxil fumarate; Telaprevir | Tibotec BVBA | Hepatitis C, HCV, HIV, AIDS | 04/09 | 04/09 | | |
NCT00933894: VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram |
|
|
| Completed | 1 | 16 | RoW | Telaprevir; Escitalopram | Tibotec BVBA | Hepatitis C | 11/09 | 11/09 | | |
NCT00958152: Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects |
|
|
| Completed | 1 | 30 | RoW | VCH-222, telaprevir | Vertex Pharmaceuticals Incorporated | Hepatitis C | 01/10 | 01/10 | | |
NCT00973388: VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers |
|
|
| Completed | 1 | 44 | RoW | Telaprevir; Moxifloxacin; Placebo | Tibotec BVBA, Vertex Pharmaceuticals Incorporated | Hepatitis C | 01/10 | 01/10 | | |
NCT00903773: VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir. |
|
|
| Completed | 1 | 24 | RoW | telaprevir | Tibotec BVBA | Hepatitis C, Kidney Diseases | 02/10 | 02/10 | | |
NCT01038167: A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults |
|
|
| Completed | 1 | 20 | US | telaprevir, cyclosporine, tacrolimus | Vertex Pharmaceuticals Incorporated, Tibotec Pharmaceutical Limited | Hepatitis C | 04/10 | 04/10 | | |
|
NCT01253551: VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir |
|
|
| Completed | 1 | 21 | US, RoW | Treatment sequence AB, Treatment sequence BA | Tibotec BVBA, Vertex Pharmaceuticals Incorporated | Hepatitis C | | 04/11 | | |
NCT01275599: Drug-Drug Interaction Study Between Telaprevir and Buprenorphine |
|
|
| Completed | 1 | 16 | US | telaprevir, buprenorphine/naloxone, Suboxone | Vertex Pharmaceuticals Incorporated, Tibotec BVBA | Hepatitis C, Opioid-Related Disorders | 04/11 | | | |
NCT01336829: TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir. |
|
|
| Completed | 1 | 33 | Europe | ETR/telaprevir, TMC278/telaprevir, telaprevir/ETR, telaprevir/TMC278 | Tibotec Pharmaceuticals, Ireland | Hepatitis C, HIV | 09/11 | 09/11 | | |
NCT01511432: A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects |
|
|
| Completed | 1 | 64 | US | telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D | Vertex Pharmaceuticals Incorporated | Chronic Hepatitis C | 06/12 | 07/12 | | |
NCT01646489: Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects |
|
|
| Completed | 1 | 5 | US | Miravirsen sodium, Miravirsen, SPC3649, Telaprevir, Incivek | Santaris Pharma A/S | Hepatitis C, Chronic Hepatitis C | 09/12 | 09/12 | | |
NCT01600976: A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment |
|
|
| Completed | 1 | 24 | Europe | telaprevir, VX-950 | Janssen Infectious Diseases BVBA | Hepatic Impairment | 10/12 | 11/12 | | |
| Completed | 1 | 26 | RoW | MP-424 | Mitsubishi Tanabe Pharma Corporation | Chronic Hepatitis C | 04/13 | 04/13 | | |
NCT01582035: Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir |
|
|
| Completed | 1 | 7 | Europe | TMC647055, TVR, PegFN, RBV | Janssen R&D Ireland | Hepatitis C | 11/13 | 11/13 | | |
NCT01704521: Viral Kinetics in HCV Clearance in Subjects With Hemophilia |
|
|
| Completed | 1 | 5 | US | PegInterferon, Ribavirin, Telaprevir | Kenneth Sherman, National Heart, Lung, and Blood Institute (NHLBI), Vertex Pharmaceuticals Incorporated, Genentech, Inc. | Chronic Hepatitis C, Hemophilia | 10/14 | 10/14 | | |
|
